Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Gains from Investment Securities (2016 - 2025)

Jaguar Health (JAGX) has disclosed Gains from Investment Securities for 11 consecutive years, with $626000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 41.33% to $626000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $227000.0, a 65.02% decrease, with the full-year FY2024 number at $5644.0, up 11418.37% from a year prior.
  • Gains from Investment Securities was $626000.0 for Q3 2025 at Jaguar Health, up from -$626000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.9 million in Q2 2022 to a low of -$2.1 million in Q4 2022.
  • A 5-year average of $110535.0 and a median of $51500.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 15303.32% in 2022; the steepest drop was 1721.09% in 2022.
  • Jaguar Health's Gains from Investment Securities stood at $128000.0 in 2021, then plummeted by 1721.09% to -$2.1 million in 2022, then surged by 119.81% to $411000.0 in 2023, then plummeted by 127.74% to -$114000.0 in 2024, then skyrocketed by 649.12% to $626000.0 in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Gains from Investment Securities are $626000.0 (Q3 2025), -$626000.0 (Q2 2025), and $341000.0 (Q1 2025).